MAIA Biotechnology, a company listed on NYSE American, has officially launched a crypto treasury strategy, as reported on October 7. The company's board has approved investing 90% of its liquid assets into leading cryptocurrencies, including Bitcoin (BTC), Ethereum (ETH), and USD Coin (USDC). This strategic move marks a significant shift in the company's asset management approach. To support this initiative, MAIA Biotechnology will establish a digital asset advisory committee. This committee will provide guidance and support for the company's cryptocurrency purchase transactions, ensuring a structured and informed approach to its new investment strategy.